CORDIS
EU research results

CORDIS

English EN
Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: the R-LiNK initiative

Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: the R-LiNK initiative

Objective

Bipolar disorder (BD) is a prevalent mental disorder and a leading cause of suicide. Lithium (Li) is the key mood stabilizer for prevention of BD relapse and suicide. Whilst many cases become asymptomatic with Li treatment, the majority show sub-optimal response. Identifying biomarkers for predicting Liresponse would enable personalization of treatment, define criteria for stratification of BD cases and further refine the clinical response phenotype.
The objectives of this proposal are to (i) improve outcomes of bipolar I disorder (BDI) cases prescribed Li through the application of stratified approaches; (ii) optimize the early prediction of lLi response using a set of multi-modal biomarkers (“blood omics”, Magnetic Resonance Imaging and Li7-Magnetic Resonance Imaging derived-markers); (iii) develop a multidisciplinary multinational network of experts to undertake this and future projects on personalized diagnostics and therapeutics; and (iv) implement new, powerful technologies to characterize brain Li distribution and the blood molecular signature of Li in responders and non-responders. This cutting edge approach will identify the eligibility criteria for treatment with Li in BD in terms of response, safety and tolerability. The assessment of each putative biomarker (singly and combined) will be guided by preliminary findings already obtained by R-LiNK; our expertise will allow exploratory analyses and innovative modelling of multi-modal data.
Likely impacts include improved outcomes and quality of life for BDI cases; development of a screening tool for clinicians; and an evaluation of the cost-effectiveness of this stratified approach. The network will develop new avenues of research on Li mechanisms of action and disease mechanisms; our industrial partnerships will enable development of medical devices to improve treatment adherence and patient’s autonomy, diagnostic kits, and tools based on the molecular signature in treatment responders.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 553 635

Participants (20)

Sort alphabetically

Sort by EU Contribution

Expand all

INSERM - TRANSFERT SA

France

EU Contribution

€ 357 375

PROVINCIA LOMBARDO VENETA - ORDINEOSPEDALIERO DI SAN GIOVANNI DI DIO- FATEBENEFRATELLI

Italy

EU Contribution

€ 401 270

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 137 568,75

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 299 235

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 408 485

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 183 750

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 137 347,50

CONSORCIO MAR PARC DE SALUT DE BARCELONA

Spain

EU Contribution

€ 133 760,50

ALCYM

France

EU Contribution

€ 270 155

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 237 500

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 284 533,75

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 843 622,50

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

France

EU Contribution

€ 347 803,75

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 404 386,25

ACOBIOM

France

EU Contribution

€ 550 000

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 349 651,25

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 798 093

MONSENSO APS

Denmark

EU Contribution

€ 381 250

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 485 360

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 137 750

Project information

Grant agreement ID: 754907

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2022

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 7 808 072,25

  • EU contribution

    € 7 702 532,25

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France